Nicotinamide Riboside and Mitochondrial Biogenesis

Sponsor: Cambridge University Hospitals NHS Foundation Trust
Collaborators: University of Cambridge MRC, Mitochondrial Biology Unit

Purpose

To investigate if nicotinamide riboside, can increase energy production and reduce symptoms in humans with mitochondrial disease.

Study Design

Open-label, single group assignment, experimental medicine study

Dose

10mg/kg for part 1, 10mg/kg 2x a day

Length of Intervention

24 hours (part 1) 4 weeks (part 2)

Status

Recruiting

Condition or Disease 

Mitochondrial Diseases
Mitochondrial Myopathies
Progressive External Ophthalmoplegia
Progressive Ophthalmoplegia
Progressive; Ophthalmoplegia, External
Mitochondria DNA Deletion
MELAS
Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Pharmacokinetic/Safety, RecruitingANAD Staff